Skip to content

Discoveries to Change Lives.

The worrying and increasing development of bacterial
resistance has led to the search of alternative substances
to antibiotics. One of them is the application of phage-encoded
lytic proteins, known as enzybiotics, on which our company is focused.

Telum Therapeutics SL is a global drug discovery biotechnology
company specializing in the use of Engineered Phage Lytic
Proteins as new antimicrobial products.

Numerous studies place the bacteriophages and, specially, their lytic enzymes, as one of the most promising alternatives to the traditional
antibiotics. For this reason, Telum Therapeutics is creating a broad bacteria and phage collection from anthropogenic and cave explorations to obtain new bacteriophages and lytic enzymes with potential antibacterial therapeutic purposes.

Telum’s mission in the field of antibiotic drug development is to give hope to patients suffering with drug resistant infections by developing new antimicrobial agents.

APEXp® under Trade secret protection

Advanced Phage Enzybiotics from exploration platform

01
Sample collection
Sample Collection
02
APEXp® Under Trade Secret
APEXp® Under Trade Secret
03
APEXp® Under Trade Secret
APEXp® Under Trade Secret
04
APEXp® Under Trade Secret
APEXp® Under Trade Secret
05
Protein Engineering
Protein Engineering
06
High throughput screening
Screening under Relevant conditions
07
Secondary Modifications
Secondary Modifications
08
Select Leading Candidates
Select Leading Candidates

APExTM

Advance Phage Enzybiotics from
exploration platform.

01
Sample collection
02
APEXp® Under Trade Secret
03
APEXp® Under Trade Secret
04
APEXp® Under Trade Secret
05
Protein Engineering
06
High throughput screening
07
Secondary Modifications
08
Select Leading Candidates

Telum Therapeutics Development Pipeline

Within our pipeline we have specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa

Candidate Name
Target Pathogen
Indication
Rights
i
Confidential
Acinetobacter baumannii CRA
Serious infections
Fully-owned
Candidate Name
Confidential
Target Pathogen
Acinetobacter baumannii CRA
Indication
Serious infections
Rights
i
Fully-owned
Preclinical Phase
Candidate Name
Target Pathogen
Indication
Rights
i
Confidential
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Cystic Fibrosis
Fully-owned
Candidate Name
Confidential
Target Pathogen
Pseudomonas aeruginosa MDR & Staphylococcus aureus MRSA
Indication
Cystic Fibrosis
Rights
i
Fully-owned
Preclinical Phase
Candidate Name
Target Pathogen
Indication
Rights
i
Confidential
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Life-threatening bacteremia
Fully-owned
Candidate Name
Confidential
Target Pathogen
Enterobacteriaceae, Pseudomonas aeruginosa Acinetobacter baumannii, including cabapenem resistant strains.
Indication
Life-threatening bacteremia
Rights
i
Fully-owned
Preclinical Phase
Candidate Name
Target Pathogen
Indication
Rights
i
Confidential
Enterococcus faecium VRE
Nosocomial infections
Fully-owned
Candidate Name
Confidential
Target Pathogen
Enterococcus faecium VRE
Indication
Nosocomial infections
Rights
i
Fully-owned
Preclinical Phase
Candidate Name
Target Pathogen
Indication
Rights
i
Confidential
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
-
Fully-owned
Candidate Name
Confidential
Target Pathogen
Acinetobacter baumannii CRA Klebsiella pneumoniae CRE & ESBL-producing
Indication
-
Rights
i
Fully-owned
Preclinical Phase